Seeking Alpha

More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a...

More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs